NUCLEIC ACID DELIVERY SYSTEM Russian patent published in 2007 - IPC A61K9/127 A61K31/343 A61K31/505 A61K31/538 C12N15/12 A61P35/00 

Abstract RU 2294192 C2

FIELD: chemical-pharmaceutical industry, biochemistry, medicine.

SUBSTANCE: invention relates to a liposome directly effecting on αvβ3-integrin receptors and comprising cationic amphiphilic substance including 1,2-dioleoyloxy-3-(N,N,N-trimethylammonium)propane chloride, neutral lipid, lipid with a direct effect having domain with a direct effect and hydrophobic domain bound with domain of a direct effect, and nucleic acid forming complex with cationic lipid. Cationic lipid presents in the amount from about 1 to about 50 molar % and indicated lipid with a direct effect presents in the amount from about 1 to about 20 molar % wherein molar percents are calculated as measured for the total number of lipid moles in liposome. Domain with a direct effect comprises a nonpeptide antagonist of αvβ3-integrin comprising 4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethyloxy]-benzoyl-2-(S)-aminoethylsulfonamino-β-alanine (compound 10) bound covalently with hydrophilic domain by amide bond. Also, invention relates to a method for inhibition of angiogenesis and involving administration to a patient needing in inhibition of angiogenesis a liposome in the therapeutically effective dose that directly effects on αvβ3-integrin receptors and comprising nucleic acid that is able to express a protein or peptide suppressing angiogenesis.

EFFECT: valuable properties of system.

27 cl, 2 tbl, 18 dwg, 8 ex

Similar patents RU2294192C2

Title Year Author Number
METHODS AND COMPOSITIONS FOR TUSC2-IMMUNOTHERAPY 2017
  • Roth, Jack, A.
  • Ji, Lin
RU2755903C2
ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS FOR USING IT 2006
  • Fan Binljan
  • Lju Tszin'Sun
  • Guo Vehj
  • U Shukhun
RU2448703C2
POLYPEPTIDES DERIVED FROM TRYPTOPHANYL-TRNA-SYNTHETASE AND USES THEREOF IN CONTROLLING OF VASCULARISATION 2002
  • Shimmel' Pol
  • Vakasugi Kejsuke
  • Frehdlehnder Martin
RU2297425C2
INTERFERON PRODRUG FOR CANCER TREATMENT 2018
  • Fu, Yang-Xin
  • Cao, Xuezhi
RU2788736C2
PEPTIDES OF DIRECTED ACTION OF VEGFR-1/NRP-1 2008
  • Paskualini Renata
  • Arap Vadikh
  • Zhiurdanu Rikardu
  • Kardo-Vila Marina
  • Valente Ana Paula
  • Seneviva Laserda De Al'Mejda Fabiu
RU2488592C2
CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY 2014
  • Brogdon Dzhennifer
  • Dzhonson Laura Aleksandra
  • Dzhun Karl Kh.
  • Lev Andreas
  • Maus Marsela
  • Sholler Dzhon
  • Okada Khidekho
RU2708032C2
MONOCLONAL ANTIBODY AND HYBRIDOMA AT CC HB 12382 AND METHOD FOR TREATING THE CASES OF ACUTE LUNG INJURY AND METHOD FOR TREATING THE CASES OF FIBROSIS 1998
  • Pitela Robert
  • Khuang Siaochzhu
  • Sheppard Din
RU2221589C2
TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR 2014
  • Brogdon Dzhennifer
  • Dzhun Karl Kh.
  • Lev Andreas
  • Maus Marsela
  • Sholler Dzhon
RU2711975C2
GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES 2016
  • Demetriou Majkl
  • Chzhou Rejmond Venkhou
RU2754661C2
METHODS AND COMPOSITIONS APPLICABLE FOR MODULATION OF ANTIOGENESIS USING PROTEIN KINASES RAF AND RAS 2000
  • Khud Dzhon
  • Ilajsiri Brajan
  • Cheresh Dehvid A.
RU2257911C2

RU 2 294 192 C2

Authors

Cheresh Dehvid A.

Khud Dzhon

Bednarski Mark

Dates

2007-02-27Published

2002-05-30Filed